Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Pharmacology
  4. Volume 17, Issue 1
  5. Article
Volume 17, Issue 1
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702
file format pdf download PDF
side by side viewer icon HTML

Abstract

In the last decade, immunotherapy (IT) has revolutionized oncology and found indications in many cancers, including hepatocellular carcinoma (HCC). In HCC, IT has become the leading systemic therapy for advanced diseases. At the same time, it carries the promise of being a valuable therapy in other settings, including intermediate-stage and unresectable disease, as a downstaging or conversion modality. More controversial is the role of IT in relationship to liver transplantation (LT): on one side, it could be a helpful tool to control or downstage HCC before LT or to treat tumor recurrence after LT, while on the other, it carries the risk of graft rejection and graft loss. This review aims to cover these concerns in depth and unravel the current literature.

2024 © 2024 The Author(s). Published by Bentham Science Publisher. The Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmp/10.2174/0118761429310703240823045808
2024-09-02
2025-05-30

  • From This Site

    /content/journals/cmp/10.2174/0118761429310703240823045808
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. Cancer today2020Available from: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=1&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D
  2. GalleP.R. FornerA. LlovetJ.M. MazzaferroV. PiscagliaF. RaoulJ-L. SchirmacherP. VilgrainV. Management of hepatocellular carcinoma.J. Hepatol.201869118223610.1016/j.jhep.2018.03.01929628281
     [Google Scholar]
  3. El-SeragH.B. Hepatocellular Carcinoma.N. Engl. J. Med.2011365121118112710.1056/NEJMra100168321992124
     [Google Scholar]
  4. ReigM. FornerA. RimolaJ. Ferrer-FàbregaJ. BurrelM. Garcia-CriadoÁ. KelleyR.K. GalleP.R. MazzaferroV. SalemR. SangroB. SingalA.G. VogelA. FusterJ. AyusoC. BruixJ. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J. Hepatol.202276368169310.1016/j.jhep.2021.11.01834801630
     [Google Scholar]
  5. VogelA. CervantesA. ChauI. DanieleB. LlovetJ.M. MeyerT. NaultJ.C. NeumannU. RickeJ. SangroB. SchirmacherP. VerslypeC. ZechC.J. ArnoldD. MartinelliE. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann. Oncol.201829Suppl. 4iv238iv25510.1093/annonc/mdy30830285213
     [Google Scholar]
  6. AngelicoR. SensiB. ManziaT.M. TisoneG. GrassiG. SignorelloA. MilanaM. LenciI. BaiocchiL. Chronic rejection after liver transplantation: Opening the Pandora’s box.World J. Gastroenterol.202127457771778310.3748/wjg.v27.i45.777134963740
     [Google Scholar]
  7. TotiL. ManziaT.M. SensiB. BlasiF. BaiocchiL. LenciI. AngelicoR. TisoneG. Towards tolerance in liver transplantation.Best Pract. Res. Clin. Gastroenterol.202154-5510177010.1016/j.bpg.2021.10177034874844
     [Google Scholar]
  8. ChengA.L. QinS. IkedaM. GalleP.R. DucreuxM. KimT.Y. LimH.Y. KudoM. BrederV. MerleP. KasebA.O. LiD. VerretW. MaN. NicholasA. WangY. LiL. ZhuA.X. FinnR.S. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J. Hepatol.202276486287310.1016/j.jhep.2021.11.03034902530
     [Google Scholar]
  9. FinnR.S. QinS. IkedaM. GalleP.R. DucreuxM. KimT.Y. KudoM. BrederV. MerleP. KasebA.O. LiD. VerretW. XuD.Z. HernandezS. LiuJ. HuangC. MullaS. WangY. LimH.Y. ZhuA.X. ChengA.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N. Engl. J. Med.2020382201894190510.1056/NEJMoa191574532402160
     [Google Scholar]
  10. PillarisettyV.G. ShahA.B. MillerG. BleierJ.I. DeMatteoR.P. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.J. Immunol.200417221009101710.4049/jimmunol.172.2.100914707074
     [Google Scholar]
  11. TayS.S. WongY.C. McDonaldD.M. WoodN.A.W. RoedigerB. SierroF. McguffogC. AlexanderI.E. BishopG.A. GambleJ.R. WeningerW. McCaughanG.W. BertolinoP. BowenD.G. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses.Proc. Natl. Acad. Sci. USA201411125E2540E254910.1073/pnas.140667411124927525
     [Google Scholar]
  12. ManziaT.M. AngelicoR. TotiL. AngelicoC. QuarantaC. ParenteA. BlasiF. IesariS. SforzaD. BaiocchiL. LerutJ. TisoneG. Longterm survival and cost-effectiveness of immunosuppression withdrawal after liver transplantation.Liver Transpl.20182491199120810.1002/lt.2529330129171
     [Google Scholar]
  13. FleckenT. SchmidtN. HildS. GostickE. DrognitzO. ZeiserR. SchemmerP. BrunsH. EiermannT. PriceD.A. BlumH.E. Neumann-HaefelinC. ThimmeR. Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell responses in hepatocellular carcinoma.Hepatology20145941415142610.1002/hep.2673124002931
     [Google Scholar]
  14. CarianiE. PilliM. BariliV. PorroE. BiasiniE. OlivaniA. Dalla ValleR. TrentiT. FerrariC. MissaleG. Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.OncoImmunology201658e115424910.1080/2162402X.2016.115424927622055
     [Google Scholar]
  15. ZhangQ.F. YinW.W. XiaY. YiY.Y. HeQ.F. WangX. RenH. ZhangD.Z. Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.Cell. Mol. Immunol.2017141081982910.1038/cmi.2016.2827321064
     [Google Scholar]
  16. FuJ. XuD. LiuZ. ShiM. ZhaoP. FuB. ZhangZ. YangH. ZhangH. ZhouC. YaoJ. JinL. WangH. YangY. FuY.X. WangF.S. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.Gastroenterology200713272328233910.1053/j.gastro.2007.03.10217570208
     [Google Scholar]
  17. GaoQ. QiuS.J. FanJ. ZhouJ. WangX.Y. XiaoY.S. XuY. LiY.W. TangZ.Y. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.J. Clin. Oncol.200725182586259310.1200/JCO.2006.09.456517577038
     [Google Scholar]
  18. ThorssonV. GibbsD.L. BrownS.D. WolfD. BortoneD.S. Ou YangT.H. Porta-PardoE. GaoG.F. PlaisierC.L. EddyJ.A. ZivE. CulhaneA.C. PaullE.O. SivakumarI.K.A. GentlesA.J. MalhotraR. FarshidfarF. ColapricoA. ParkerJ.S. MoseL.E. VoN.S. LiuJ. LiuY. RaderJ. DhankaniV. ReynoldsS.M. BowlbyR. CalifanoA. CherniackA.D. AnastassiouD. BedognettiD. MokrabY. NewmanA.M. RaoA. ChenK. KrasnitzA. HuH. MaltaT.M. NoushmehrH. PedamalluC.S. BullmanS. OjesinaA.I. LambA. ZhouW. ShenH. ChoueiriT.K. WeinsteinJ.N. GuinneyJ. SaltzJ. HoltR.A. RabkinC.S. LazarA.J. SerodyJ.S. DemiccoE.G. DisisM.L. VincentB.G. ShmulevichI. Caesar-JohnsonS.J. DemchokJ.A. FelauI. KasapiM. FergusonM.L. HutterC.M. SofiaH.J. TarnuzzerR. WangZ. YangL. ZenklusenJ.C. ZhangJ.J. ChudamaniS. LiuJ. LollaL. NareshR. PihlT. SunQ. WanY. WuY. ChoJ. DeFreitasT. FrazerS. GehlenborgN. GetzG. HeimanD.I. KimJ. LawrenceM.S. LinP. MeierS. NobleM.S. SaksenaG. VoetD. ZhangH. BernardB. ChambweN. DhankaniV. KnijnenburgT. KramerR. LeinonenK. LiuY. MillerM. ReynoldsS. ShmulevichI. ThorssonV. ZhangW. AkbaniR. BroomB.M. HegdeA.M. JuZ. KanchiR.S. KorkutA. LiJ. LiangH. LingS. LiuW. LuY. MillsG.B. NgK-S. RaoA. RyanM. WangJ. WeinsteinJ.N. ZhangJ. AbeshouseA. ArmeniaJ. ChakravartyD. ChatilaW.K. de BruijnI. GaoJ. GrossB.E. HeinsZ.J. KundraR. LaK. LadanyiM. LunaA. NissanM.G. OchoaA. PhillipsS.M. ReznikE. Sanchez-VegaF. SanderC. SchultzN. SheridanR. SumerS.O. SunY. TaylorB.S. WangJ. ZhangH. AnurP. PetoM. SpellmanP. BenzC. StuartJ.M. WongC.K. YauC. HayesD.N. ParkerJ.S. WilkersonM.D. AllyA. BalasundaramM. BowlbyR. BrooksD. CarlsenR. ChuahE. DhallaN. HoltR. JonesS.J.M. KasaianK. LeeD. MaY. MarraM.A. MayoM. MooreR.A. MungallA.J. MungallK. RobertsonA.G. SadeghiS. ScheinJ.E. SipahimalaniP. TamA. ThiessenN. TseK. WongT. BergerA.C. BeroukhimR. CherniackA.D. CibulskisC. GabrielS.B. GaoG.F. HaG. MeyersonM. SchumacherS.E. ShihJ. KucherlapatiM.H. KucherlapatiR.S. BaylinS. CopeL. DanilovaL. BootwallaM.S. LaiP.H. MaglinteD.T. Van Den BergD.J. WeisenbergerD.J. AumanJ.T. BaluS. BodenheimerT. FanC. HoadleyK.A. HoyleA.P. JefferysS.R. JonesC.D. MengS. MieczkowskiP.A. MoseL.E. PerouA.H. PerouC.M. RoachJ. ShiY. SimonsJ.V. SkellyT. SolowayM.G. TanD. VeluvoluU. FanH. HinoueT. LairdP.W. ShenH. ZhouW. BellairM. ChangK. CovingtonK. CreightonC.J. DinhH. DoddapaneniH.V. DonehowerL.A. DrummondJ. GibbsR.A. GlennR. HaleW. HanY. HuJ. KorchinaV. LeeS. LewisL. LiW. LiuX. MorganM. MortonD. MuznyD. SantibanezJ. ShethM. ShinbrotE. WangL. WangM. WheelerD.A. XiL. ZhaoF. HessJ. AppelbaumE.L. BaileyM. CordesM.G. DingL. FronickC.C. FultonL.A. FultonR.S. KandothC. MardisE.R. McLellanM.D. MillerC.A. SchmidtH.K. WilsonR.K. CrainD. CurleyE. GardnerJ. LauK. MalleryD. MorrisS. PaulauskisJ. PennyR. SheltonC. SheltonT. ShermanM. ThompsonE. YenaP. BowenJ. Gastier-FosterJ.M. GerkenM. LeraasK.M. LichtenbergT.M. RamirezN.C. WiseL. ZmudaE. CorcoranN. CostelloT. HovensC. CarvalhoA.L. de CarvalhoA.C. FregnaniJ.H. Longatto-FilhoA. ReisR.M. Scapulatempo-NetoC. SilveiraH.C.S. VidalD.O. BurnetteA. EschbacherJ. HermesB. NossA. SinghR. AndersonM.L. CastroP.D. IttmannM. HuntsmanD. KohlB. LeX. ThorpR. AndryC. DuffyE.R. LyadovV. PaklinaO. SetdikovaG. ShabuninA. TavobilovM. McPhersonC. WarnickR. BerkowitzR. CramerD. FeltmateC. HorowitzN. KibelA. MutoM. RautC.P. MalykhA. Barnholtz-SloanJ.S. BarrettW. DevineK. FulopJ. OstromQ.T. ShimmelK. WolinskyY. SloanA.E. De RoseA. GiulianteF. GoodmanM. KarlanB.Y. HagedornC.H. EckmanJ. HarrJ. MyersJ. TuckerK. ZachL.A. DeyarminB. HuH. KvecherL. LarsonC. MuralR.J. SomiariS. VichaA. ZelinkaT. BennettJ. IacoccaM. RabenoB. SwansonP. LatourM. LacombeL. TêtuB. BergeronA. McGrawM. StaugaitisS.M. ChabotJ. HibshooshH. SepulvedaA. SuT. WangT. PotapovaO. VoroninaO. DesjardinsL. MarianiO. Roman-RomanS. SastreX. SternM-H. ChengF. SignorettiS. BerchuckA. BignerD. LippE. MarksJ. McCallS. McLendonR. SecordA. SharpA. BeheraM. BratD.J. ChenA. DelmanK. ForceS. KhuriF. MaglioccaK. MaithelS. OlsonJ.J. OwonikokoT. PickensA. RamalingamS. ShinD.M. SicaG. Van MeirE.G. ZhangH. EijckenboomW. GillisA. KorpershoekE. LooijengaL. OosterhuisW. StoopH. van KesselK.E. ZwarthoffE.C. CalatozzoloC. CuppiniL. CuzzubboS. DiMecoF. FinocchiaroG. MatteiL. PerinA. PolloB. ChenC. HouckJ. LohavanichbutrP. HartmannA. StoehrC. StoehrR. TaubertH. WachS. WullichB. KyclerW. MurawaD. WiznerowiczM. ChungK. EdenfieldW.J. MartinJ. BaudinE. BubleyG. BuenoR. De RienzoA. RichardsW.G. KalkanisS. MikkelsenT. NoushmehrH. ScarpaceL. GirardN. AymerichM. CampoE. GinéE. GuillermoA.L. Van BangN. HanhP.T. PhuB.D. TangY. ColmanH. EvasonK. DottinoP.R. MartignettiJ.A. GabraH. JuhlH. AkeredoluT. StepaS. HoonD. AhnK. KangK.J. BeuschleinF. BreggiaA. BirrerM. BellD. BoradM. BryceA.H. CastleE. ChandanV. ChevilleJ. CoplandJ.A. FarnellM. FlotteT. GiamaN. HoT. KendrickM. KocherJ-P. KoppK. MoserC. NagorneyD. O’BrienD. O’NeillB.P. PatelT. PetersenG. QueF. RiveraM. RobertsL. SmallridgeR. SmyrkT. StantonM. ThompsonR.H. TorbensonM. YangJ.D. ZhangL. BrimoF. AjaniJ.A. GonzalezA.M.A. BehrensC. BondarukJ. BroaddusR. CzerniakB. EsmaeliB. FujimotoJ. GershenwaldJ. GuoC. LazarA.J. LogothetisC. Meric-BernstamF. MoranC. RamondettaL. RiceD. SoodA. TamboliP. ThompsonT. TroncosoP. TsaoA. WistubaI. CarterC. HayduL. HerseyP. JakrotV. KakavandH. KeffordR. LeeK. LongG. MannG. QuinnM. SawR. ScolyerR. ShannonK. SpillaneA. Stretch SynottM. ThompsonJ. WilmottJ. Al-AhmadieH. ChanT.A. GhosseinR. GopalanA. LevineD.A. ReuterV. SingerS. SinghB. TienN.V. BroudyT. MirsaidiC. NairP. DrwiegaP. MillerJ. SmithJ. ZarenH. ParkJ-W. HungN.P. KebebewE. LinehanW.M. MetwalliA.R. PacakK. PintoP.A. SchiffmanM. SchmidtL.S. VockeC.D. WentzensenN. WorrellR. YangH. MoncrieffM. GoparajuC. MelamedJ. PassH. BotnariucN. CaramanI. CernatM. ChemencedjiI. ClipcaA. DorucS. GorincioiG. MuraS. PirtacM. StanculI. TcaciucD. AlbertM. AlexopoulouI. ArnaoutA. BartlettJ. EngelJ. GilbertS. ParfittJ. SekhonH. ThomasG. RasslD.M. RintoulR.C. BifulcoC. TamakawaR. UrbaW. HaywardN. TimmersH. AntenucciA. FaccioloF. GraziG. MarinoM. MerolaR. de KrijgerR. Gimenez-RoqueploA-P. PichéA. ChevalierS. McKercherG. BirsoyK. BarnettG. BrewerC. FarverC. NaskaT. PennellN.A. RaymondD. SchileroC. SmolenskiK. WilliamsF. MorrisonC. BorgiaJ.A. LiptayM.J. PoolM. SederC.W. JunkerK. OmbergL. DinkinM. ManikhasG. AlvaroD. BragazziM.C. CardinaleV. CarpinoG. GaudioE. CheslaD. CottinghamS. DubinaM. MoiseenkoF. DhanasekaranR. BeckerK-F. JanssenK-P. Slotta-HuspeninaJ. Abdel-RahmanM.H. AzizD. BellS. CebullaC.M. DavisA. DuellR. ElderJ.B. HiltyJ. KumarB. LangJ. LehmanN.L. MandtR. NguyenP. PilarskiR. RaiK. SchoenfieldL. SenecalK. WakelyP. HansenP. LechanR. PowersJ. TischlerA. GrizzleW.E. SextonK.C. KastlA. HendersonJ. PortenS. WaldmannJ. FassnachtM. AsaS.L. SchadendorfD. CouceM. GraefenM. HulandH. SauterG. SchlommT. SimonR. TennstedtP. OlabodeO. NelsonM. BatheO. CarrollP.R. ChanJ.M. DisaiaP. GlennP. KelleyR.K. LandenC.N. PhillipsJ. PradosM. SimkoJ. Smith-McCuneK. VandenBergS. RogginK. FehrenbachA. KendlerA. SifriS. SteeleR. JimenoA. CareyF. ForgieI. MannelliM. CarneyM. HernandezB. CamposB. Herold-MendeC. JungkC. UnterbergA. von DeimlingA. BosslerA. GalbraithJ. JacobusL. KnudsonM. KnutsonT. MaD. MilhemM. SigmundR. GodwinA.K. MadanR. RosenthalH.G. AdebamowoC. AdebamowoS.N. BoussioutasA. BeerD. GiordanoT. Mes-MassonA-M. SaadF. BocklageT. LandrumL. MannelR. MooreK. MoxleyK. PostierR. WalkerJ. ZunaR. FeldmanM. ValdiviesoF. DhirR. LuketichJ. PineroE.M.M. Quintero-AguiloM. CarlottiC.G.Jr Dos SantosJ.S. KempR. SankarankutyA. TirapelliD. CattoJ. AgnewK. SwisherE. CreaneyJ. RobinsonB. ShelleyC.S. GodwinE.M. KendallS. ShipmanC. BradfordC. CareyT. HaddadA. MoyerJ. PetersonL. PrinceM. RozekL. WolfG. BowmanR. FongK.M. YangI. KorstR. RathmellW.K. Fantacone-CampbellJ.L. HookeJ.A. KovatichA.J. ShriverC.D. DiPersioJ. DrakeB. GovindanR. HeathS. LeyT. Van TineB. WesterveltP. RubinM.A. LeeJ.I. AredesN.D. MariamidzeA. The Immune Landscape of Cancer.Immunity2018484812830.e1410.1016/j.immuni.2018.03.02329628290
     [Google Scholar]
  19. YeungO.W.H. LoC.M. LingC.C. QiX. GengW. LiC.X. NgK.T.P. ForbesS.J. GuanX.Y. PoonR.T.P. FanS.T. ManK. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma.J. Hepatol.201562360761610.1016/j.jhep.2014.10.02925450711
     [Google Scholar]
  20. HanY. ChenZ. YangY. JiangZ. GuY. LiuY. LinC. PanZ. YuY. JiangM. ZhouW. CaoX. Human CD14 + CTLA-4 + regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.Hepatology201459256757910.1002/hep.2669423960017
     [Google Scholar]
  21. ZhongM. ZhongC. CuiW. WangG. ZhengG. LiL. ZhangJ. RenR. GaoH. WangT. LiX. CheJ. GohdaE. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.BMC Cancer201919143910.1186/s12885‑019‑5670‑931088527
     [Google Scholar]
  22. LiuY. XunZ. MaK. LiangS. LiX. ZhouS. SunL. LiuY. DuY. GuoX. CuiT. ZhouH. WangJ. YinD. SongR. ZhangS. CaiW. MengF. GuoH. ZhangB. YangD. BaoR. HuQ. WangJ. YeY. LiuL. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.J. Hepatol.202378477078210.1016/j.jhep.2023.01.01136708811
     [Google Scholar]
  23. TopalianS.L. DrakeC.G. PardollD.M. Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell201527445046110.1016/j.ccell.2015.03.00125858804
     [Google Scholar]
  24. BlankC. GajewskiT.F. MackensenA. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.Cancer Immunol. Immunother.200554430731410.1007/s00262‑004‑0593‑x15599732
     [Google Scholar]
  25. ButteM.J. KeirM.E. PhamduyT.B. SharpeA.H. FreemanG.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.Immunity200727111112210.1016/j.immuni.2007.05.01617629517
     [Google Scholar]
  26. BlankC. MackensenA. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.Cancer Immunol. Immunother.200756573974510.1007/s00262‑006‑0272‑117195077
     [Google Scholar]
  27. SeidelJ.A. OtsukaA. KabashimaK. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.Front. Oncol.201888610.3389/fonc.2018.0008629644214
     [Google Scholar]
  28. LiS. YaoD. WangL. WuW. QiuL. YaoM. YaoN. ZhangH. YuD. NiQ. Expression characteristics of hypoxia-inducible factor-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma.Hepat. Mon.2011111082182810.5812/kowsar.1735143X.130522224081
     [Google Scholar]
  29. VoronT. ColussiO. MarcheteauE. PernotS. NizardM. PointetA.L. LatrecheS. BergayaS. BenhamoudaN. TanchotC. StockmannC. CombeP. BergerA. ZinzindohoueF. YagitaH. TartourE. TaiebJ. TermeM. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.J. Exp. Med.2015212213914810.1084/jem.2014055925601652
     [Google Scholar]
  30. AguiarR.B. MoraesJ.Z. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors.Front. Immunol.201910102310.3389/fimmu.2019.0102331156623
     [Google Scholar]
  31. YauT. ParkJ.W. FinnR.S. ChengA.L. MathurinP. EdelineJ. KudoM. HardingJ.J. MerleP. RosmorducO. WyrwiczL. SchottE. ChooS.P. KelleyR.K. SieghartW. AssenatE. ZauchaR. FuruseJ. Abou-AlfaG.K. El-KhoueiryA.B. MeleroI. BegicD. ChenG. NeelyJ. WisniewskiT. TschaikaM. SangroB. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol.2022231779010.1016/S1470‑2045(21)00604‑534914889
     [Google Scholar]
  32. Abou-AlfaGK LauG KudoM ChanSL KelleyRK FuruseJ Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid202218EVIDoa210007010.1056/EVIDoa2100070
     [Google Scholar]
  33. SangroB. ChanS.L. KelleyR.K. LauG. KudoM. SukeepaisarnjaroenW. YarchoanM. De ToniE.N. FuruseJ. KangY.K. GalleP.R. RimassaL. HeurguéA. TamV.C. Van DaoT. ThungappaS.C. BrederV. OstapenkoY. ReigM. MakowskyM. PaskowM.J. GuptaC. KurlandJ.F. NegroA. Abou-AlfaG.K. AzevedoS. BraghiroliM.I. GirottoG. BragagnoliA. BrancoR. FaccioA. MorettoA. SkareN. DutraJ. ViolaL. ViannaK. MetonF. SetteC. FaulhaberA. TamV.C. CoutureF. BiagiJ. CastelH. MulderK. KoY-J. ZbukK. WelchS. BeaudoinA. HeurguéA. AssenatE. ArchambeaudI. TougeronD. PeronJ-M. GilabertM. BronowickiJ-P. CattanS. BlancJ-F. BouattourM. PhelipJ-M. BoigeV. MichelP. FrinA-C. De ToniE.N. BerresM-L. VogelA. BergT. EttrichT. WaldschmidtD. WedemeyerH.H. WornsM-A. BitzerM. WeissK-H. LauG. ChanS.L. YauT. TaiY.P. LeeA.S. ThungappaS.C. NL.K. Sureshchand OstwalV. AshokK.K. MittalS. GoyalH. SrinivasanS. BiswasG. MohanM. LimayeS. AsarawalaN. RimassaL. FalconeA. GianniL. GasbarriniA. DanieleB. AvalloneA. Paolo FrassinetiG.L. RoilaF. KudoM. KawaokaT. MorimotoM. TakikawaY. KatoN. YamashitaT. OsakiY. MotomuraK. TateishiR. OhkawaK. WadaY. OnishiH. SasahiraN. InabaY. KurosakiM. TsujiK. TakeiY. AramakiT. HagiharaA. FuruseJ. KiokaK. KogaH. SasakiY. NumataK. TadaT. KawaguchiY. NadanoS. VasilyevA. BrederV. LipatovO. DvorkinM. ZarubenkovO. KutukovaS. PonomarevR. ShostkaK. AlyasovaA. TopuzovE. SevertsevA. PetrovY. EryginD. BerdovB. KangY-K. TakW-Y. ParkJ-W. LimH.Y. HeoJ. KimJ.H. KimT-Y. ChoiH.J. VarelaM. Reig MonzonM.E. SangroB. MartinC.G. PonceC.G. LópezC. ChengA-L. ChaoY. FengY-H. JengL-B. HungC-H. HouM-M. Wang Tsang-En WangJ-H. YenC-J. SukeepaisarnjaroenW. SunpaweravongP. CharoentumC. TanasanvimonS. SirachainanE. UngtrakulT. PrasongsookN. ManeenilK. JitpewngarmW. OstapenkoY. SkoryiD. BondarenkoI. ShparykY. TrukhinD. HotkoY. UrsolG. KryzhanivskaA. Abou-AlfaG.K. ModyK. DayyaniF. Al-RajabiR. YarchoanM. GandhiS. CryslerO. HeA.R. ReevesJ. BaharyN. MahipalA. KelleyR.K. DasguptaA. RoweJ. ThotaR. BegM. MorseM. ChoiS. CrocenziT. SomerB. AbramsT. DenlingerC. ZhangY. SharmaN. DaoT.V. ThinhN.T. Tuyet PhuongL.T. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.Ann. Oncol.202435544845710.1016/j.annonc.2024.02.00538382875
     [Google Scholar]
  34. YauT. KangY.K. KimT.Y. El-KhoueiryA.B. SantoroA. SangroB. MeleroI. KudoM. HouM.M. MatillaA. TovoliF. KnoxJ.J. Ruth HeA. El-RayesB.F. Acosta-RiveraM. LimH.Y. NeelyJ. ShenY. WisniewskiT. AndersonJ. HsuC. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.JAMA Oncol.2020611e20456410.1001/jamaoncol.2020.456433001135
     [Google Scholar]
  35. FinnR.S. IkedaM. ZhuA.X. SungM.W. BaronA.D. KudoM. OkusakaT. KobayashiM. KumadaH. KanekoS. PrachtM. MamontovK. MeyerT. KubotaT. DutcusC.E. SaitoK. SiegelA.B. DubrovskyL. ModyK. LlovetJ.M. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.J. Clin. Oncol.202038262960297010.1200/JCO.20.0080832716739
     [Google Scholar]
  36. MazzaferroV. RegaliaE. DociR. AndreolaS. PulvirentiA. BozzettiF. MontaltoF. AmmatunaM. MorabitoA. GennariL. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N. Engl. J. Med.19963341169370010.1056/NEJM1996031433411048594428
     [Google Scholar]
  37. VitaleA. CabibboG. IavaroneM. ViganòL. PinatoD.J. PonzianiF.R. LaiQ. Casadei-GardiniA. CelsaC. GalatiG. GambatoM. CrocettiL. RenzulliM. GianniniE.G. FarinatiF. TrevisaniF. CilloU. BaccaraniU. BrancaccioG. CozzolongoR. CucchettiA. De MatthaeisN. Di SandroS. FamularoS. FinottiM. FoschiF.G. GhinolfiD. GuarracinoM. GruttadauriaS. GuarinoM. KostandiniA. LenciI. Levi SandriG.B. ManziaT.M. MarascoG. MasaroneM. MazzarelliC. MelandroF. MieleL. MoriscoF. NicoliniD. PaganoD. PelizzaroF. PieriG. PiscagliaF. Plaz TorresM.C. PravisaniR. RendinaM. RomanoF. RussoF.P. SaccoR. SangiovanniA. SpositoC. TortoraR. TovoliF. ViganòM. VioliP. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept.Lancet Oncol.2023247e312e32210.1016/S1470‑2045(23)00186‑937414020
     [Google Scholar]
  38. VitaleA. AngelicoR. SensiB. LaiQ. KauffmannE. ScaleraI. SerenariM. GinesiniM. RomanoP. FurlanettoA. D’AmicoF. What is the role of minimally invasive liver surgery in treating patients with hepatocellular carcinoma on cirrhosis?Cancers (Basel)202416596610.3390/cancers1605096638473327
     [Google Scholar]
  39. RoayaieS. ObeidatK. SpositoC. MarianiL. BhooriS. PellegrinelliA. LabowD. LlovetJ.M. SchwartzM. MazzaferroV. Resection of hepatocellular cancer ≤2 cm: Results from two Western centers.Hepatology20135741426143510.1002/hep.2583222576353
     [Google Scholar]
  40. GabrielsonA. WuY. WangH. JiangJ. KallakuryB. GatalicaZ. ReddyS. KleinerD. FishbeinT. JohnsonL. IslandE. SatoskarR. BanovacF. JhaR. KachhelaJ. FengP. ZhangT. TesfayeA. PrinsP. LoffredoC. MarshallJ. WeinerL. AtkinsM. HeA.R. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC.Cancer Immunol. Res.20164541943010.1158/2326‑6066.CIR‑15‑011026968206
     [Google Scholar]
  41. KasebA.O. HasanovE. CaoH.S.T. XiaoL. VautheyJ.N. LeeS.S. YavuzB.G. MohamedY.I. QayyumA. JindalS. DuanF. BasuS. YadavS.S. NicholasC. SunJ.J. Singh RaghavK.P. RashidA. CarterK. ChunY.S. TzengC.W.D. SakamuriD. XuL. SunR. CristiniV. BerettaL. YaoJ.C. WolffR.A. AllisonJ.P. SharmaP. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.Lancet Gastroenterol. Hepatol.20227320821810.1016/S2468‑1253(21)00427‑135065057
     [Google Scholar]
  42. QinS. ChenM. ChengA.L. KasebA.O. KudoM. LeeH.C. YoppA.C. ZhouJ. WangL. WenX. HeoJ. TakW.Y. NakamuraS. NumataK. UguenT. HsiehchenD. ChaE. HackS.P. LianQ. MaN. SpahnJ.H. WangY. WuC. ChowP.K.H. ThompsonA. DantaM. PoursoltanP. KiberuA. ChittajalluR. SoodS. StauberR. PinterM. Peck-RadosavljevicM. DecaesteckerJ. CuyleP-J. VersetG. Van VlierbergheH. De AzevedoS. AndradeL. Cunha JúniorA. FariaL. YenC.T. ColliL. AsselahJ. KavanP. MarquezV. BrahmaniaM. LiQ. XingB. GuoY. ChenZ. ZhaoH. PengT. WangL. WangL. LiuH. WuF. QinL. ZhengQ. YingJ. LiH. WenT. QinS. WenX. LiuY. ChenM. WangB. BaiY. HeY. ZhaoH. ZhouD. DaiC. TengG. CuiS. GaoY. ZhangX. LuZ. YinT. DingY. JiaW. XiaY. SunB. XiaQ. YuanY. SunH. ShiX. GuzmánA. CorralesL. KralZ. PriesterP. KubalaE. BlancJ.F. BourliereM. PeronJ.M. BorgC. BronowickiJ-P. GanneN. DecaensT. UguenT. HeurgueA. TrojanJ. Gonzalez-CarmonaM.A. RoderburgC. EttrichT. SchottenC. KandulskiA. YauT. ChanL. ScartozziM. MasiG. FanelloS. BattezzatiP.M. LeonardiF. GhidiniM. NumataK. MorimotoM. HidakaH. TsuchiyaK. YamashitaT. KatoN. KudoM. HagiharaA. KogaH. ArakawaT. NakamuraI. KawamuraY. KawaokaT. ShimadaM. HasegawaK. MarusawaH. NakamuraS. HiraokaA. HayashiH. TakedaS. LeeH.C. PaikS.W. KimD.Y. LeeJ.I. JeongS-H. KimW. TakW.Y. HeoJ. KimH. ChonH.J. CheongJ. YoonS.K. YoonJ-H. VillalobosR. Martinez RodriguezJ.L. Oyervides JuarezV. HernándezC.A. KlumpenH-J. de Vos-GeelenJ. GaneE. MontenegroP. Torres MattosC. JanczewskaE. KaweckiM. Nowakowska-ZajdelE. FedenkoA. GranovD. AlyasovaA. SekachevaM. LedinE. SamolJ. TohH.C. Calvo CamposM. Gomez MartinC. Lopez LopezC. Muñoz MartinA.J. Calleja PaneroJ.L. Montero AlvarezJ.L. Reig MonzónM. Delgado MingoranceI. Minguez RosiqueB. ChengA.L. HuangY-H. LinS-M. HuangJ-F. YuM-L. SuW-W. KorphaisarnK. ManeenilK. SamdaengpanC. TharavichitkulE. OzgurogluM. KoseF. HarputluogluH. BuchschacherG. ThuluvathP. XiongH. PatelM. GoldP. LiD. BrooksG. MasoodA. PatelR. GeorgeB. SalgiaR. ManjiG. CrowM. KasebA. DuganM. KadakiaK. KardoshA. GibbsJ. ShahA. BurrisH.III HsiehchenD. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Lancet2023402104151835184710.1016/S0140‑6736(23)01796‑837871608
     [Google Scholar]
  43. DuffyA.G. UlahannanS.V. Makorova-RusherO. RahmaO. WedemeyerH. PrattD. DavisJ.L. HughesM.S. HellerT. ElGindiM. UppalaA. KorangyF. KleinerD.E. FiggW.D. VenzonD. SteinbergS.M. VenkatesanA.M. KrishnasamyV. Abi-JaoudehN. LevyE. WoodB.J. GretenT.F. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J. Hepatol.201766354555110.1016/j.jhep.2016.10.02927816492
     [Google Scholar]
  44. NiizekiT. TokunagaT. TakamiY. WadaY. HaradaM. ShibataM. NakaoK. SasakiR. HiraiF. ShakadoS. YoshizumiT. ItohS. YatsuhashiH. BekkiS. IdoA. MawatariS. HondaK. SugimotoR. SenjuT. TakahashiH. KuwashiroT. MaeshiroT. NakamutaM. AratakeY. YamashitaT. OtsukaY. MatsumotoS. SohdaT. ShimoseS. MurotaniK. TanakaY. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A propensity score matching analysis.Target. Oncol.202217664365310.1007/s11523‑022‑00921‑x36272060
     [Google Scholar]
  45. ZhuX.D. HuangC. ShenY.H. XuB. GeN.L. JiY. QuX.D. ChenL. ChenY. LiM.L. ZhuJ.J. TangZ.Y. ZhouJ. FanJ. SunH.C. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus Anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma.Ann. Surg. Oncol.20233052782279010.1245/s10434‑022‑12530‑z36178565
     [Google Scholar]
  46. LiW. PeiY. WangZ. LiuJ. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.Front. Oncol.20221293086810.3389/fonc.2022.93086835978834
     [Google Scholar]
  47. WuJ.Y. YinZ.Y. BaiY.N. ChenY.F. ZhouS.Q. WangS.J. ZhouJ.Y. LiY.N. QiuF.N. LiB. YanM.L. Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A multicenter retrospective study.J. Hepatocell. Carcinoma202181233124010.2147/JHC.S33242034676181
     [Google Scholar]
  48. ChenS. WuZ. ShiF. MaiQ. WangL. WangF. ZhuangW. ChenX. ChenH. XuB. LaiJ. GuoW. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: A retrospective study.J. Cancer Res. Clin. Oncol.202214882115212510.1007/s00432‑021‑03767‑434453221
     [Google Scholar]
  49. PeiY. LiW. WangZ. LiuJ. Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis.Front. Oncol.20221297882310.3389/fonc.2022.97882336176393
     [Google Scholar]
  50. LiX. ChenJ. WangX. BaiT. LuS. WeiT. TangZ. HuangC. ZhangB. LiuB. LiL. WuF. Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.Front. Oncol.202313111068910.3389/fonc.2023.111068936793614
     [Google Scholar]
  51. LinK.Y. LinZ.W. ChenQ.J. LuoL.P. ZhangJ.X. ChenJ.H. WangK. TaiS. ZhangZ-B. WangS. ZhangJ-Y. YouW-Y. WangB. YouP-H. LinK-C. YangT. ZengY-Y. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.Hepatol. Int.20231761477148910.1007/s12072‑023‑10561‑6
     [Google Scholar]
  52. LuoL. HeY. ZhuG. XiaoY. SongS. GeX. WangT. XieJ. DengW. HuZ. ShanR. Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?J. Hepatocell. Carcinoma202291353136810.2147/JHC.S38896536578526
     [Google Scholar]
  53. MazzaferroV. LlovetJ.M. MiceliR. BhooriS. SchiavoM. MarianiL. CameriniT. RoayaieS. SchwartzM.E. GraziG.L. AdamR. NeuhausP. SalizzoniM. BruixJ. FornerA. De CarlisL. CilloU. BurroughsA.K. TroisiR. RossiM. GerundaG.E. LerutJ. BelghitiJ. BoinI. GugenheimJ. RochlingF. Van HoekB. MajnoP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.Lancet Oncol.2009101354310.1016/S1470‑2045(08)70284‑519058754
     [Google Scholar]
  54. YaoF.Y. MehtaN. FlemmingJ. DodgeJ. HameedB. FixO. HiroseR. FidelmanN. KerlanR.K.Jr RobertsJ.P. Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria.Hepatology20156161968197710.1002/hep.2775225689978
     [Google Scholar]
  55. PostowM.A. SidlowR. HellmannM.D. Immune-related adverse events associated with immune checkpoint blockade.N. Engl. J. Med.2018378215816810.1056/NEJMra170348129320654
     [Google Scholar]
  56. ChenG.H. WangG.B. HuangF. QinR. YuX.J. WuR.L. HouL.J. YeZ.H. ZhangX.H. ZhaoH.C. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.Transpl. Immunol.20216610138610.1016/j.trim.2021.10138633744409
     [Google Scholar]
  57. SchnickelG.T. FabbriK. HosseiniM. MiselM. BerumenJ. ParekhJ. MekeelK. DehghanY. KonoY. AjmeraV. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab.Am. J. Transplant.20222261699170410.1111/ajt.1696535080128
     [Google Scholar]
  58. NordnessM.F. HamelS. GodfreyC.M. ShiC. JohnsonD.B. GoffL.W. O’DellH. PerriR.E. AlexopoulosS.P. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?Am. J. Transplant.202020387988310.1111/ajt.1561731550417
     [Google Scholar]
  59. TabrizianP. FlormanS.S. SchwartzM.E. PD-1 inhibitor as bridge therapy to liver transplantation?Am. J. Transplant.20212151979198010.1111/ajt.1644833316117
     [Google Scholar]
  60. LominadzeZ. HillK. ShaikM.R. CanakisJ.P. BourmafM. Adams-MardiC. AbutalebA. MishraL. ShettyK. Immunotherapy for hepatocellular carcinoma in the setting of liver transplantation: A review.Int. J. Mol. Sci.2023243235810.3390/ijms2403235836768686
     [Google Scholar]
  61. GaoQ. AnwarI.J. AbrahamN. BarbasA.S. Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors.Cancers20211324630710.3390/cancers1324630734944927
     [Google Scholar]
  62. Schwacha-EipperB. MinciunaI. BanzV. DufourJ.F. Immunotherapy as a downstaging therapy for liver transplantation.Hepatology20207241488149010.1002/hep.3123432171041
     [Google Scholar]
  63. AbdelrahimM. EsmailA. UmoruG. WesthartK. AbudayyehA. SahariaA. GhobrialR.M. Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: A case report.Curr. Oncol.20222964267427310.3390/curroncol2906034135735450
     [Google Scholar]
  64. Lizaola-MayoB.C. MathurA.K. BoradM.J. JadlowiecC.C. Lam-HimlinD.M. CoreyR.L. IqbalS. OkuboK. ByrneT.J. MossA.A. AqelB.A. ChascsaD.M. Immunotherapy as a downstaging tool for liver transplantation in hepatocellular carcinoma.Am. J. Gastroenterol.2021116122478248010.14309/ajg.000000000000139135134013
     [Google Scholar]
  65. TabrizianP. HolznerM.L. MehtaN. HalazunK. AgopianV.G. YaoF. BusuttilR.W. RobertsJ. EmondJ.C. SamsteinB. BrownR.S.Jr NajjarM. ChapmanW.C. DoyleM.M. FlormanS.S. SchwartzM.E. LlovetJ.M. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma.JAMA Surg.2022157977978810.1001/jamasurg.2022.280035857294
     [Google Scholar]
  66. Fernandez-SevillaE. AllardM.A. SeltenJ. GolseN. VibertE. Sa CunhaA. CherquiD. CastaingD. AdamR. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?Liver Transpl.201723444044710.1002/lt.2474228187493
     [Google Scholar]
  67. De ToniE.N. GerbesA.L. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient.Gastroenterology201715261631163310.1053/j.gastro.2017.01.06328384452
     [Google Scholar]
  68. FriendB.D. VenickR.S. McDiarmidS.V. ZhouX. NainiB. WangH. FarmerD.G. BusuttilR.W. FedermanN. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.Pediatr. Blood Cancer20176412e2668210.1002/pbc.2668228643391
     [Google Scholar]
  69. VarkarisA. LewisD.W. NugentF.W. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma.Am. J. Gastroenterol.2017112121895189610.1038/ajg.2017.38729215617
     [Google Scholar]
  70. MunkerS. De ToniE.N. Use of checkpoint inhibitors in liver transplant recipients.United European Gastroenterol. J.20186797097310.1177/205064061877463130228883
     [Google Scholar]
  71. Al JarroudiO. UlusakaryaA. AlmohamadW. AfqirS. MorereJ.F. Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: A report of three cases.Cureus20201210e1115010.7759/cureus.1115033133796
     [Google Scholar]
  72. GassmannD. WeilerS. MertensJ.C. ReinerC.S. VrugtB. NägeliM. ManganaJ. MüllhauptB. JenniF. MisselwitzB. Liver allograft failure after nivolumab treatment-a case report with systematic literature research.Transplant. Direct201848e37610.1097/TXD.000000000000081430255136
     [Google Scholar]
  73. RammohanA. ReddyM.S. FaroukM. VargeseJ. RelaM. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?Hepatology20186731166116810.1002/hep.2957529023959
     [Google Scholar]
  74. AuK.P. ChokK.S.H. Immunotherapy after liver transplantation: Where are we now?World J. Gastrointest. Surg.202113101267127810.4240/wjgs.v13.i10.126734754394
     [Google Scholar]
  75. DeLeonT.T. SalomaoM.A. AqelB.A. SonbolM.B. YokodaR.T. AliA.H. MossA.A. MathurA.K. ChascsaD.M. RakelaJ. BryceA.H. BoradM.J. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.J. Gastrointest. Oncol.2018961054106210.21037/jgo.2018.07.0530603124
     [Google Scholar]
  76. SzymanskaS. Markiewicz-KijewskaM. PyzlakM. Karkucinska-WienckowskaA. CiopinskiM. CzubkowskiP. KalicińskiP. Immunotherapy after liver transplantation: Where are we now?World J. Gastrointest. Surg.202313101267127810.3390/jcm1213426937445304
     [Google Scholar]
  77. SzymanskaS. Markiewicz-KijewskaM. PyzlakM. Karkucinska-WienckowskaA. CiopinskiM. CzubkowskiP. KalicińskiP. Tissue expression of programmed cell death 1 Ligand1 (PD-L1) in biopsies of transplant livers of pediatric patients as a possible marker of acute cellular rejection.J. Clin. Med.20231213426910.3390/jcm1213426937445304
     [Google Scholar]
/content/journals/cmp/10.2174/0118761429310703240823045808
Loading
Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation
Curr Mol Pharmacol 17, e18761429310703 (2024); https://doi.org/10.2174/0118761429310703240823045808
/content/journals/cmp/10.2174/0118761429310703240823045808
/content/journals/cmp/10.2174/0118761429310703240823045808
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Downstaging; Hepatocellular carcinoma; Immune checkpoint; Immunotherapy; Liver transplantation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test